The lack of participation of minorities in clinical research is having a grave effect on the efficiency of
clinical trials. In order to improve participation there is a need to gain trust and reliability of minorities to the pharma industry.
The challenge lies in removing the stigma that so many indecent projects beforehand have brought
about and what that indicates moving forward for minority consumers and clinical development. This serves as a public health issue, because it directly correlates with the disparities in health care
education and options in the minority community.